Leeches & Maggots
Ancient Creatures, Cleared by the FDA
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
These are genuinely validated, the rare traditional practices that crossed fully into evidence-based medicine. In 2004 the FDA cleared medicinal leeches and, months earlier, medical maggots, making them the first living organisms cleared as medical devices. Leech therapy has clinical-study tissue-salvage success rates around 70-80% for venous congestion in skin flaps and reattached digits, and remains preferred in many microsurgery centers. Maggot debridement therapy has evidence for cleaning and improving healing in chronic wounds (diabetic, venous, and pressure ulcers), sometimes faster than surgical debridement. Important honesty: the strong evidence is for these specific indications. Off-label uses promoted by some practitioners (leeches for osteoarthritis, low back pain, general "detox") have limited or no good evidence, with the leech-for-pain evidence base described as comparable in quality to acupuncture. So: validated for defined surgical and wound-care uses, unproven for the broader claims.
Reference only. Not medical advice.
What can go wrong
Used correctly in a clinical setting, both are relatively safe, but real risks exist and these are supervised medical procedures, not home remedies. Leeches can transmit bacteria, especially Aeromonas species, that cause wound infection, so prophylactic antibiotics are standard practice; ciprofloxacin has been common but resistant Aeromonas infections are documented, and combination prophylaxis is often preferred. Leech treatment also causes ongoing blood loss and prolonged oozing by design, and a meaningful share of patients need transfusion, so people on anticoagulants or with bleeding disorders need particular caution. Maggot therapy can cause pain, itching, or a crawling sensation and depends on correct containment of the larvae. The greatest danger comes from non-medical, off-label use: wild or unsterile organisms can introduce serious infection, and using either for unproven conditions in place of an effective treatment risks harm and delay. Anyone considering these treatments, and anyone who is immunocompromised, pregnant, or on blood thinners, should work only with a qualified clinician who can weigh the indication and manage the risks.
Two of the oldest tools in medicine are back in the operating room and the wound clinic. Medicinal leeches were used for bloodletting across the ancient world for thousands of years, and battlefield surgeons repeatedly noticed that maggot-infested wounds often stayed clean. Both faded with antiseptic surgery and antibiotics, then returned as evidence accumulated, and in 2004 they became the first living organisms the FDA cleared as medical devices. The mechanisms are specific. Leech saliva contains hirudin, a thrombin inhibitor that keeps blood moving and relieves venous congestion in a reattached finger or a skin flap whose vein is not draining; case series report tissue salvage in roughly 65 to 85 percent of treated flaps. Medical maggots secrete enzymes that dissolve dead tissue and can debride a chronic ulcer faster than a gel dressing. The honest read is narrower than the folklore: these are validated for defined surgical and wound-care jobs, the healing benefit for maggots is less clear than the debridement benefit, and off-label detox claims are unsupported. Real risks, notably Aeromonas infection from leeches, make these supervised medical procedures rather than home remedies.
Leeches and maggots, used for thousands of years, are now the first living organisms FDA-cleared as medical devices, validated for microsurgery and wound debridement.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
The mechanisms are well understood. A feeding leech injects saliva containing hirudin, a potent anticoagulant, which keeps blood flowing and relieves venous congestion in tissue that has been reattached or grafted (the bite oozes for hours afterward, decompressing the tissue). Medical maggots (disinfected blow-fly larvae) secrete digestive enzymes that selectively dissolve dead, necrotic tissue while sparing healthy tissue (debridement), kill bacteria (disinfection), and stimulate healing. Both are mechanically and biochemically specific, not mystical.
What people get wrong
Often saidLeeches and maggots are primitive superstition with no place in real medicine.
ActuallyBoth have been FDA-cleared medical devices since 2004, the first living organisms ever cleared. Leeches are used to relieve venous congestion in reattached digits and flaps, with case-series salvage rates around 65 to 85 percent, and medical maggots are cleared to debride chronic wounds such as pressure, venous, and diabetic-foot ulcers.
Often saidIf they work for surgery, leech and maggot therapy must help many other conditions too.
ActuallyThe clearances are narrow and indication-specific. Maggots are cleared for debriding chronic wounds, not for curing them outright, and the VenUS II trial found they sped debridement without speeding overall healing. Leech benefit is documented for venous congestion in microsurgery and, in a smaller controlled literature, for knee-osteoarthritis pain; general detox claims are not supported.
Often saidYou can just apply store-bought or wild leeches and maggots at home.
ActuallyMedically used organisms are purpose-raised under controlled, disinfected conditions and applied with prophylaxis and monitoring. Wild or unsterile leeches carry Aeromonas and other bacteria; wild fly larvae can invade healthy tissue. Aeromonas accounts for roughly 88 percent of leech-associated infections, which is why supervised medical use with antibiotic prophylaxis is the standard.
Who profits, and who pushes back
FDA & microsurgery centers
Cleared leeches and maggots as the first living medical devices in 2004; leeches remain preferred in many centers for venous congestion in flaps and reattachments.
Wound-care research
Support maggot therapy for cleaning and healing chronic diabetic, venous, and pressure ulcers, sometimes faster than surgical debridement.
Evidence reviewers
Note that leech therapy for pain conditions like osteoarthritis and low back pain has limited evidence, comparable in quality to acupuncture, unlike the validated surgical use.
Infection-control clinicians
Flag Aeromonas and other infection risk with leeches (prophylactic antibiotics standard) and warn against unsterile, non-medical use of either organism.
Where the research comes from
Most of the published research on this comes from one place. 80% of it is from Global modern microsurgery. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Global modern microsurgery | 80% |
| Historic Europe, Egypt, S. Asia | 75% |
| Wound-care clinics worldwide | 72% |
How we got here
Leeching is among the oldest recorded treatments. Egyptian tomb paintings from roughly 1500 BCE appear to show it, and the Indian Sushruta Samhita (commonly dated to the mid first millennium BCE) describes leech application, jalaukavacharana, within its surgical teaching; the physician-deity Dhanvantari is often depicted holding a leech. Greek, Roman, Arabic, and Persian physicians folded leeches into humoral bloodletting, and demand in nineteenth-century Europe was so heavy it nearly exhausted wild Hirudo medicinalis. Maggot wound-cleaning has a parallel military lineage: Napoleon's surgeon Dominique-Jean Larrey noted in the early 1800s that larvae consumed dead tissue while sparing living flesh, and Confederate surgeons made similar observations. William Baer, an orthopedic surgeon at Johns Hopkins, is credited with founding modern maggot therapy in the 1920s and 1930s after seeing infested but clean wounds on wounded soldiers in the First World War. Both practices receded with antiseptic surgery and penicillin, then revived from the 1980s onward.
- c. 1500 BCEEgyptian tomb art appears to depict medicinal leeching
- mid 1st millennium BCESushruta Samhita in India describes leech therapy (jalaukavacharana) in surgical practice
- early 1800sNapoleon's surgeon Larrey records that maggots eat dead tissue but spare living flesh
- 19th centuryLeech demand peaks in Europe, nearly exhausting wild Hirudo medicinalis populations
- 1920s-1930sWilliam Baer at Johns Hopkins establishes modern sterile maggot therapy; roughly 1000 North American surgeons adopt it
- 1940s-1960sBoth practices fade as antiseptic surgery and antibiotics take over
- 1980s-2000sMicrosurgery and chronic-wound needs drive clinical revival and controlled study
- 2004FDA clears medicinal leeches (K040187) and Medical Maggots as the first living organisms marketed as medical devices
- 2009VenUS II randomized trial (267 patients) shows maggots debride leg ulcers faster than hydrogel but do not speed healing
- 2024FDA moves regulatory oversight of leeches and maggots from CDRH to CBER (product codes NRN and NQK)
- 2026Cuprina's MEDIFLY becomes the first US-cleared Lucilia cuprina maggot debridement product
How it is understood
Two of the oldest creatures in the healer's kit have made a striking return to the modern hospital. Medicinal leeches (Hirudo medicinalis) were used for bloodletting across ancient Egypt, Greece, India, and Europe for thousands of years, so heavily in the 19th century that the preferred species became endangered. Maggots, meanwhile, were noticed for centuries by battlefield and military surgeons, who observed that soldiers whose wounds became infested with certain fly larvae often healed better and cleaner than those without. Both fell out of favor as modern antiseptic surgery rose, then were rediscovered in the late 20th century. Today they are not folklore but tools: applied in microsurgery wards and wound clinics under medical supervision.
At a glance
- Leech action
- Hirudin anticoagulant relieves venous congestion
- Maggot action
- Enzymes debride necrotic tissue, disinfect
- FDA cleared
- 2004, first living medical devices
- Leech flap-salvage
- ~70-80% success in studies
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Leeches & Maggots. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
FDA cleared medicinal leeches as a medical device in June 2004 for venous congestion in microsurgery
FDA transferred leeches (NRN) and maggots (NQK) from CDRH to CBER on Dec 30, 2024 without changing requirements; both cleared 2004
Medical Maggots cleared 2004 for debriding chronic wounds; K072438 later dressing/product; Lucilia sericata
Hirudin is a thrombin inhibitor; flap tissue-salvage ~78% (Whitaker); Aeromonas ~88% of leech infections; ~14.4% infection rate; prophylaxis standard
Leech flap-salvage success ranged roughly 65-85% across 41 studies in a systematic review; Aeromonas prophylaxis advised
Leech therapy in flap salvage: Systematic review and practical recommendations (PubMed 27427444)
VenUS II RCT (267 patients): larval therapy debrided leg ulcers faster than hydrogel but did not improve healing and increased pain
Maggot therapy debrides chronic wounds effectively but overall study quality is limited; effect on healing is mixed
Meta-analysis of controlled trials (237 patients) finds moderate to strong short-term pain reduction from leech therapy in knee osteoarthritis; calls for further high-quality RCTs
Michalsen RCT: leech therapy reduced knee-osteoarthritis pain versus topical diclofenac (Annals of Internal Medicine 2003)
Ciprofloxacin-resistant Aeromonas hydrophila infection can occur despite prophylaxis during leech therapy
William Baer founded modern sterile maggot therapy at Johns Hopkins in the 1920s-30s; Larrey's Napoleonic battlefield observations of maggots sparing living tissue
How Maggots Made It Back into Mainstream Medicine, American Council on Science and Health
Ancient leech history: Egyptian tomb art (~1500 BCE), Sushruta Samhita in India, Greek/Roman/Unani humoral use, 19th-century European overharvesting
History of Medicinal Leech Therapy, American Society of Hirudotherapy
Cuprina's MEDIFLY (Lucilia cuprina) received first US FDA 510(k) clearance for that species in June 2026, substantially equivalent to Medical Maggots (Lucilia sericata)
Aetna clinical policy classifies medicinal leech and maggot therapy as covered/medically necessary for defined surgical and wound indications
Bio-Surgery: Medicinal Leech Therapy and Medical Maggots, Aetna Clinical Policy Bulletin 0556